Curated News
By: NewsRamp Editorial Staff
October 20, 2026
SS Innovations Brings Robotic Cardiac Surgery to Sri Lanka with SSi Mantra 3.0
TLDR
- SS Innovations launched Sri Lanka's first robotic cardiac program with SSi Mantra 3.0, boosting its global footprint and recurring revenue potential.
- SS Innovations' SSi Mantra 3.0 system enables robotic cardiac surgery through precise robotic-assisted procedures like left internal mammary artery takedown.
- SS Innovations' affordable robotic surgery program in Sri Lanka expands access to advanced cardiac care, improving patient outcomes and healthcare equity.
- Sri Lanka's first robotic cardiac surgery program completed over 25 procedures in three weeks using SS Innovations' SSi Mantra 3.0 system.
Impact - Why it Matters
This news matters because it demonstrates how affordable robotic surgery is moving from concept to clinical reality in emerging markets. By enabling Sri Lanka’s first robotic cardiac program, SS Innovations is proving that advanced surgical care can be delivered at lower cost points, potentially widening access to minimally invasive procedures globally. The rapid procedure volume—25 cases in three weeks—signals strong physician adoption and validates the SSi Mantra’s usability. For investors, the combination of rising installations, procedure growth, and forthcoming regulatory milestones in the U.S. and Europe suggests a scalable business model with recurring revenue from instruments and consumables. As healthcare systems worldwide grapple with cost and access challenges, SS Innovations’ progress offers a template for expanding robotic surgery beyond high-income countries.
Summary
SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, has launched Sri Lanka’s first robotic cardiac surgery program at Kings Hospital Colombo, powered by its SSi Mantra 3.0 surgical robotic system. The program commenced with a robotic-assisted left internal mammary artery takedown performed by company founder and Chairman Dr. Sudhir Srivastava alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva. Notably, the hospital completed more than 25 robotic procedures within the first three weeks, underscoring rapid adoption and clinical confidence in the technology.
The launch is part of SS Innovations’ broader international expansion. At the end of the second quarter of 2026, the company reported 224 cumulative SSi Mantra installations across 12 countries. Quarterly revenue increased 39% year over year to $13.9 million, while robotic procedures rose 143% to 2,528, highlighting increased utilization of installed systems and potential opportunities for recurring revenue from surgical instruments and consumables. SS Innovations is also pursuing broader market access, with U.S. FDA clearance targeted for the first quarter of 2027 and European CE marking targeted for the end of 2026. To view the full article, visit https://nnw.fm/DJ6dI.
SS Innovations International develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. Headquartered in India, SS Innovations is a U.S. company focused on expanding the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. For more information, visit SSInnovations.com or LinkedIn.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, SS Innovations Brings Robotic Cardiac Surgery to Sri Lanka with SSi Mantra 3.0
